The main findings of this retrospective, observational study, are the following: first, it is confirmed that, among hypertensive subjects, the use of ACE inhibitors or ARBs up to two years preceding SARS-CoV-2 infection did not affect the severity of COVID-19. Here, ACE is linked to COVID-19.